Periodontal Diseases
Conditions
Brief summary
This study aimed to determine CCL19/MIP3beta(β) and CCL20/MIP3alpha(α) in the gingival crevicular fluid (GCF) of the patients with different periodontitis phenotypes. A total of 72 individuals, 24 with Stage III Grade B periodontitis (Group 1), 24 with Stage III Grade C periodontitis (Group 2), and 24 periodontally healthy (control group) (Group 3), were included in the study. GCF and clinical periodontal parameters were obtained at baseline. MIP3β and MIP3α levels in GCF were determined by ELISA.
Interventions
DIAGNOSTIC_TESTRoutine periodontal examination
In all of the patients, the following indexes were used routinely for the periodontal examination: Sillness-Löe's plaque index (PI) (Silness & Löe, 1964), Löe-Sillness's gingival index (GI)(Löe & Silness, 1963), probing depth (PD) to measure the extent and severity of periodontal disease, clinical attachment level (CAL), and bleeding on probing (BOP)(Ainamo & Bay, 1975) to determine activity. In addition, routine radiographic evaluations were performed to determine bone levels.GCF samples were collected using standardized filter papers.
Sponsors
Ordu University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
22 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Have at least 20 natural teeth, excluding third molars. * Periodontitis patients had at least two non-adjacent sites per quadrant with probing depth (PD) ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm with gingival inflammation, and alveolar bone loss affecting \>30% of the teeth, as detected on clinical and radiographical examinations. * Periodontally healthy control group had no sign of gingival inflammation, no PD \> 3mm and no evidence of attachment or bone loss
Exclusion criteria
* History of systemic disease. * Regular use of any drugs which can effect the immune system or inflammatory response in the 6 months preceding the start of the study. * Periodontal treatment during last 6 months that could affect periodontal status. * Smoking. * History of radiotherapy or chemotherapy. * Current pregnancy, lactation or menopause.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CCL19/MIP3beta(β) levels | Baseline | CCL19/MIP3beta(β) levels in the gingival crevicular fluid (GCF) of the all groups |
| CCL20/MIP3alpha(α) levels | Baseline | CCL20/MIP3alpha(α) levels in the gingival crevicular fluid (GCF) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CCL19/MIP3beta(β) levels and clinical parameters | Baseline | Correlation between CCL19/MIP3beta(β) levels in the gingival crevicular fluid (GCF) of the all groups and all clinical parameters |
| CCL20/MIP3alpha(α) levels and clinical parameters | Baseline | Correlation between CCL20/MIP3alpha(α) levels in the gingival crevicular fluid (GCF) of the all groups and all clinical parameters |
Countries
Turkey (Türkiye)
Outcome results
None listed